Paul J. Coleman - Publications

Affiliations: 
1994 Indiana University, Bloomington, Bloomington, IN, United States 

42 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2015 Raheem IT, Schreier JD, Fuerst J, Gantert L, Hostetler ED, Huszar S, Joshi A, Kandebo M, Kim SH, Li J, Ma B, McGaughey G, Sharma S, Shipe WD, Uslaner J, ... ... Coleman PJ, et al. Discovery of pyrazolopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia. Bioorganic & Medicinal Chemistry Letters. PMID 26602277 DOI: 10.1016/J.Bmcl.2015.11.013  0.48
2015 Hostetler ED, Fan H, Joshi AD, Zeng Z, Eng W, Gantert L, Holahan M, Meng X, Miller P, O'Malley S, Purcell M, Riffel K, Salinas C, Williams M, Ma B, ... ... Coleman PJ, et al. Preclinical Characterization of the Phosphodiesterase 10A PET Tracer [(11)C]MK-8193. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. PMID 26596571 DOI: 10.1007/S11307-015-0910-0  0.48
2015 Raheem I, Walji A, Klein D, Sanders JM, Powell D, Abeywickrema P, Barbe G, Bennet A, Clas SD, Dubost D, Embrey M, Grobler J, Hafey M, Hartingh TJ, Hazuda DJ, ... ... Coleman PJ, et al. Discovery of 2-Pyridinone Aminals: A Prodrug Strategy to Advance a Second Generation of HIV-1 Integrase Strand Transfer Inhibitors. Journal of Medicinal Chemistry. PMID 26397965 DOI: 10.1021/acs.jmedchem.5b01037  0.48
2015 Shipe WD, Sharik SS, Barrow JC, McGaughey GB, Theberge CR, Uslaner JM, Yan Y, Renger JJ, Smith SM, Coleman PJ, Cox CD. Discovery and Optimization of a Series of Pyrimidine-Based Phosphodiesterase 10A (PDE10A) Inhibitors through Fragment Screening, Structure-Based Design, and Parallel Synthesis. Journal of Medicinal Chemistry. PMID 26378882 DOI: 10.1021/Acs.Jmedchem.5B00983  0.48
2015 Roecker AJ, Cox CD, Coleman PJ. Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia. Journal of Medicinal Chemistry. PMID 26317591 DOI: 10.1021/Acs.Jmedchem.5B00832  0.48
2015 Cox CD, Hostetler ED, Flores BA, Evelhoch JL, Fan H, Gantert L, Holahan M, Eng W, Joshi A, McGaughey G, Meng X, Purcell M, Raheem IT, Riffel K, Yan Y, ... ... Coleman PJ, et al. Discovery of [(11)C]MK-8193 as a PET tracer to measure target engagement of phosphodiesterase 10A (PDE10A) inhibitors. Bioorganic & Medicinal Chemistry Letters. PMID 26077491 DOI: 10.1016/J.Bmcl.2015.05.080  0.48
2015 Kuduk SD, Skudlarek JW, DiMarco CN, Bruno JG, Pausch MH, O'Brien JA, Cabalu TD, Stevens J, Brunner J, Tannenbaum PL, Garson SL, Savitz AT, Harrell CM, Gotter AL, Winrow CJ, ... ... Coleman PJ, et al. Identification of MK-8133: An orexin-2 selective receptor antagonist with favorable development properties. Bioorganic & Medicinal Chemistry Letters. 25: 2488-92. PMID 25981685 DOI: 10.1016/j.bmcl.2015.04.066  0.48
2015 Rudd MT, Butcher JW, Nguyen KT, McIntyre CJ, Romano JJ, Gilbert KF, Bush KJ, Liverton NJ, Holloway MK, Harper S, Ferrara M, DiFilippo M, Summa V, Swestock J, Fritzen J, ... ... Coleman PJ, et al. P2-quinazolinones and bis-macrocycles as new templates for next-generation hepatitis C virus NS3/4a protease inhibitors: discovery of MK-2748 and MK-6325. Chemmedchem. 10: 727-35. PMID 25759009 DOI: 10.1002/cmdc.201402558  0.48
2015 Roecker AJ, Mercer SP, Bergman JM, Gilbert KF, Kuduk SD, Harrell CM, Garson SL, Fox SV, Gotter AL, Tannenbaum PL, Prueksaritanont T, Cabalu TD, Cui D, Lemaire W, Winrow CJ, ... ... Coleman PJ, et al. Discovery of diazepane amide DORAs and 2-SORAs enabled by exploration of isosteric quinazoline replacements. Bioorganic & Medicinal Chemistry Letters. PMID 25613676 DOI: 10.1016/J.Bmcl.2014.12.081  0.48
2015 Raheem IT, Breslin MJ, Bruno J, Cabalu TD, Cooke A, Cox CD, Cui D, Garson S, Gotter AL, Fox SV, Harrell CM, Kuduk SD, Lemaire W, Prueksaritanont T, Renger JJ, ... ... Coleman PJ, et al. Discovery of piperidine ethers as selective orexin receptor antagonists (SORAs) inspired by filorexant. Bioorganic & Medicinal Chemistry Letters. 25: 444-50. PMID 25577040 DOI: 10.1016/j.bmcl.2014.12.056  0.48
2015 Walji AM, Sanchez RI, Clas SD, Nofsinger R, de Lera Ruiz M, Li J, Bennet A, John C, Bennett DJ, Sanders JM, Di Marco CN, Kim SH, Balsells J, Ceglia SS, Dang Q, ... ... Coleman PJ, et al. Discovery of MK-8970: an acetal carbonate prodrug of raltegravir with enhanced colonic absorption. Chemmedchem. 10: 245-52. PMID 25469982 DOI: 10.1002/cmdc.201402393  0.48
2015 Uslaner JM, Renger JJ, Coleman PJ, Winrow CJ. A new class of hypnotic compounds for the treatment of insomnia: The dual orexin receptor antagonists Orexin and Sleep: Molecular, Functional and Clinical Aspects. 323-338. DOI: 10.1007/978-3-319-23078-8_17  0.48
2014 Roecker AJ, Reger TS, Mattern MC, Mercer SP, Bergman JM, Schreier JD, Cube RV, Cox CD, Li D, Lemaire W, Bruno JG, Harrell CM, Garson SL, Gotter AL, Fox SV, ... ... Coleman PJ, et al. Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia. Bioorganic & Medicinal Chemistry Letters. 24: 4884-90. PMID 25248679 DOI: 10.1016/J.Bmcl.2014.08.041  0.48
2014 Gotter AL, Garson SL, Stevens J, Munden RL, Fox SV, Tannenbaum PL, Yao L, Kuduk SD, McDonald T, Uslaner JM, Tye SJ, Coleman PJ, Winrow CJ, Renger JJ. Differential sleep-promoting effects of dual orexin receptor antagonists and GABAA receptor modulators. Bmc Neuroscience. 15: 109. PMID 25242351 DOI: 10.1186/1471-2202-15-109  0.48
2014 Shah U, Jayne C, Chackalamannil S, Velázquez F, Guo Z, Buevich A, Howe JA, Chase R, Soriano A, Agrawal S, Rudd MT, McCauley JA, Liverton NJ, Romano J, Bush K, ... Coleman PJ, et al. Novel Quinoline-Based P2-P4 Macrocyclic Derivatives As Pan-Genotypic HCV NS3/4a Protease Inhibitors. Acs Medicinal Chemistry Letters. 5: 264-9. PMID 24900818 DOI: 10.1021/ml400466p  0.48
2014 Uslaner JM, Winrow CJ, Gotter AL, Roecker AJ, Coleman PJ, Hutson PH, Le AD, Renger JJ. Selective orexin 2 receptor antagonism blocks cue-induced reinstatement, but not nicotine self-administration or nicotine-induced reinstatement. Behavioural Brain Research. 269: 61-5. PMID 24746488 DOI: 10.1016/J.Bbr.2014.04.012  0.48
2014 Roecker AJ, Mercer SP, Harrell CM, Garson SL, Fox SV, Gotter AL, Prueksaritanont T, Cabalu TD, Cui D, Lemaire W, Winrow CJ, Renger JJ, Coleman PJ. Discovery of dual orexin receptor antagonists with rat sleep efficacy enabled by expansion of the acetonitrile-assisted/diphosgene-mediated 2,4-dichloropyrimidine synthesis. Bioorganic & Medicinal Chemistry Letters. 24: 2079-85. PMID 24704030 DOI: 10.1016/J.Bmcl.2014.03.052  0.48
2014 Kuduk SD, Skudlarek JW, Di Marco CN, Bruno JG, Pausch MA, O'Brien JA, Cabalu TD, Stevens J, Brunner J, Tannenbaum PL, Gotter AL, Winrow CJ, Renger JJ, Coleman PJ. Synthesis and evaluation of carbon-linked analogs of dual orexin receptor antagonist filorexant. Bioorganic & Medicinal Chemistry Letters. 24: 1784-9. PMID 24630562 DOI: 10.1016/j.bmcl.2014.02.026  0.48
2014 Miller RA, Winrow CJ, Spellman DS, Song Q, Reiss DR, Conway JP, Taylor RR, Coleman PJ, Hendrickson RC, Renger JJ. Quantitative proteomics in laser capture microdissected sleep nuclei from rat brain. Journal of Neurogenetics. 28: 136-45. PMID 24579665 DOI: 10.3109/01677063.2014.883389  0.48
2014 McGaughey G, Bayly CI, Cox CD, Schreier JD, Breslin MJ, Bogusky M, Pitzenberger S, Ball R, Coleman PJ. Shaping suvorexant: application of experimental and theoretical methods for driving synthetic designs. Journal of Computer-Aided Molecular Design. 28: 5-12. PMID 24488306 DOI: 10.1007/s10822-014-9710-x  0.48
2014 Roecker AJ, Mercer SP, Schreier JD, Cox CD, Fraley ME, Steen JT, Lemaire W, Bruno JG, Harrell CM, Garson SL, Gotter AL, Fox SV, Stevens J, Tannenbaum PL, Prueksaritanont T, ... ... Coleman PJ, et al. Discovery of 5''-chloro-N-[(5,6-dimethoxypyridin-2-yl)methyl]-2,2':5',3''-terpyridine-3'-carboxamide (MK-1064): a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia. Chemmedchem. 9: 311-22. PMID 24376006 DOI: 10.1002/Cmdc.201300447  0.48
2013 Ramirez AD, Gotter AL, Fox SV, Tannenbaum PL, Yao L, Tye SJ, McDonald T, Brunner J, Garson SL, Reiss DR, Kuduk SD, Coleman PJ, Uslaner JM, Hodgson R, Browne SE, et al. Dual orexin receptor antagonists show distinct effects on locomotor performance, ethanol interaction and sleep architecture relative to gamma-aminobutyric acid-A receptor modulators. Frontiers in Neuroscience. 7: 254. PMID 24399926 DOI: 10.3389/Fnins.2013.00254  0.48
2013 Mercer SP, Roecker AJ, Garson S, Reiss DR, Meacham Harrell C, Murphy KL, Bruno JG, Bednar RA, Lemaire W, Cui D, Cabalu TD, Tang C, Prueksaritanont T, Hartman GD, Young SD, ... ... Coleman PJ, et al. Discovery of 2,5-diarylnicotinamides as selective orexin-2 receptor antagonists (2-SORAs). Bioorganic & Medicinal Chemistry Letters. 23: 6620-4. PMID 24215892 DOI: 10.1016/J.Bmcl.2013.10.045  0.48
2013 Gotter AL, Winrow CJ, Brunner J, Garson SL, Fox SV, Binns J, Harrell CM, Cui D, Yee KL, Stiteler M, Stevens J, Savitz A, Tannenbaum PL, Tye SJ, McDonald T, ... ... Coleman PJ, et al. The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy threshold. Bmc Neuroscience. 14: 90. PMID 23981345 DOI: 10.1186/1471-2202-14-90  0.48
2013 Fox SV, Gotter AL, Tye SJ, Garson SL, Savitz AT, Uslaner JM, Brunner JI, Tannenbaum PL, McDonald TP, Hodgson R, Yao L, Bowlby MR, Kuduk SD, Coleman PJ, Hargreaves R, et al. Quantitative electroencephalography within sleep/wake states differentiates GABAA modulators eszopiclone and zolpidem from dual orexin receptor antagonists in rats. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 38: 2401-8. PMID 23722242 DOI: 10.1038/Npp.2013.139  0.48
2013 Uslaner JM, Tye SJ, Eddins DM, Wang X, Fox SV, Savitz AT, Binns J, Cannon CE, Garson SL, Yao L, Hodgson R, Stevens J, Bowlby MR, Tannenbaum PL, Brunner J, ... ... Coleman PJ, et al. Orexin receptor antagonists differ from standard sleep drugs by promoting sleep at doses that do not disrupt cognition. Science Translational Medicine. 5: 179ra44. PMID 23552372 DOI: 10.1126/Scitranslmed.3005213  0.48
2013 Smith SM, Uslaner JM, Cox CD, Huszar SL, Cannon CE, Vardigan JD, Eddins D, Toolan DM, Kandebo M, Yao L, Raheem IT, Schreier JD, Breslin MJ, Coleman PJ, Renger JJ. The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey. Neuropharmacology. 64: 215-23. PMID 22750078 DOI: 10.1016/J.Neuropharm.2012.06.013  0.48
2012 Harper S, McCauley JA, Rudd MT, Ferrara M, DiFilippo M, Crescenzi B, Koch U, Petrocchi A, Holloway MK, Butcher JW, Romano JJ, Bush KJ, Gilbert KF, McIntyre CJ, Nguyen KT, ... ... Coleman PJ, et al. Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor. Acs Medicinal Chemistry Letters. 3: 332-6. PMID 24900473 DOI: 10.1021/ml300017p  0.48
2012 Raheem IT, Breslin MJ, Fandozzi C, Fuerst J, Hill N, Huszar S, Kandebo M, Kim SH, Ma B, McGaughey G, Renger JJ, Schreier JD, Sharma S, Smith S, Uslaner J, ... ... Coleman PJ, et al. Discovery of tetrahydropyridopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia. Bioorganic & Medicinal Chemistry Letters. 22: 5903-8. PMID 22892116 DOI: 10.1016/J.Bmcl.2012.07.072  0.48
2012 Gotter AL, Roecker AJ, Hargreaves R, Coleman PJ, Winrow CJ, Renger JJ. Orexin receptors as therapeutic drug targets. Progress in Brain Research. 198: 163-88. PMID 22813974 DOI: 10.1016/B978-0-444-59489-1.00010-0  0.48
2012 Gotter AL, Webber AL, Coleman PJ, Renger JJ, Winrow CJ. International Union of Basic and Clinical Pharmacology. LXXXVI. Orexin receptor function, nomenclature and pharmacology. Pharmacological Reviews. 64: 389-420. PMID 22759794 DOI: 10.1124/pr.111.005546  0.48
2012 Summa V, Ludmerer SW, McCauley JA, Fandozzi C, Burlein C, Claudio G, Coleman PJ, Dimuzio JM, Ferrara M, Di Filippo M, Gates AT, Graham DJ, Harper S, Hazuda DJ, Huang Q, et al. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrobial Agents and Chemotherapy. 56: 4161-7. PMID 22615282 DOI: 10.1128/AAC.00324-12  0.48
2012 Coleman PJ, Barrow JC. Challenges and opportunities in neuroscience research. Chemmedchem. 7: 339-41. PMID 22383223 DOI: 10.1002/cmdc.201200075  0.48
2012 Coleman PJ, Schreier JD, Cox CD, Breslin MJ, Whitman DB, Bogusky MJ, McGaughey GB, Bednar RA, Lemaire W, Doran SM, Fox SV, Garson SL, Gotter AL, Harrell CM, Reiss DR, et al. Discovery of [(2R,5R)-5-{[(5-fluoropyridin-2-yl)oxy]methyl}-2-methylpiperidin-1-yl][5-methyl-2-(pyrimidin-2-yl)phenyl]methanone (MK-6096): a dual orexin receptor antagonist with potent sleep-promoting properties. Chemmedchem. 7: 415-24, 337. PMID 22307992 DOI: 10.1002/cmdc.201200025  0.48
2012 Winrow CJ, Gotter AL, Cox CD, Tannenbaum PL, Garson SL, Doran SM, Breslin MJ, Schreier JD, Fox SV, Harrell CM, Stevens J, Reiss DR, Cui D, Coleman PJ, Renger JJ. Pharmacological characterization of MK-6096 - a dual orexin receptor antagonist for insomnia. Neuropharmacology. 62: 978-87. PMID 22019562 DOI: 10.1016/j.neuropharm.2011.10.003  0.48
2011 Winrow CJ, Gotter AL, Cox CD, Doran SM, Tannenbaum PL, Breslin MJ, Garson SL, Fox SV, Harrell CM, Stevens J, Reiss DR, Cui D, Coleman PJ, Renger JJ. Promotion of sleep by suvorexant-a novel dual orexin receptor antagonist. Journal of Neurogenetics. 25: 52-61. PMID 21473737 DOI: 10.3109/01677063.2011.566953  0.48
2011 Coleman PJ, Cox CD, Roecker AJ. Discovery of dual orexin receptor antagonists (DORAs) for the treatment of insomnia. Current Topics in Medicinal Chemistry. 11: 696-725. PMID 21261591 DOI: 10.2174/1568026611109060696  0.48
2007 Coleman PJ, Kerkering JC. Measuring mining safety with injury statistics: lost workdays as indicators of risk. Journal of Safety Research. 38: 523-33. PMID 18023637 DOI: 10.1016/j.jsr.2007.06.005  0.01
2002 Coleman PJ, Goddard JM. Harlequin syndrome following internal jugular vein catheterization in an adult under general anesthetic. Anesthesiology. 97: 1041. PMID 12357195  0.01
1995 Williams DR, Coleman PJ. Studies on the dolabellanes: Stereoselective transannular cyclizations of dolabelladiene macrocycles Tetrahedron Letters. 36: 39-42. DOI: 10.1016/0040-4039(94)02164-7  0.92
1995 Williams DR, Coleman PJ. Total synthesis of neodolabellenol Tetrahedron Letters. 36: 35-38. DOI: 10.1016/0040-4039(94)02163-6  0.92
1993 Williams DR, Coleman PJ, Henry SS. Synthesis strategies for marine diterpenes. Total synthesis of the clavularanes Journal of the American Chemical Society. 115: 11654-11655. DOI: 10.1021/Ja00077A097  0.92
Show low-probability matches.